Applied DNA Sciences, Inc. (APDN)
USD 0.23
(1.26%)
USD 0.23
(1.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -9.59 Million USD | 51.14% |
| 2022 | -12.67 Million USD | -120.59% |
| 2021 | -11.68 Million USD | 23.25% |
| 2020 | -12.24 Million USD | -68.96% |
| 2019 | -8.06 Million USD | 32.89% |
| 2018 | -11.09 Million USD | 6.68% |
| 2017 | -11.93 Million USD | -3.82% |
| 2016 | -11.49 Million USD | -239.24% |
| 2015 | -7.36 Million USD | 68.98% |
| 2014 | -11.82 Million USD | -365.41% |
| 2013 | -9.85 Million USD | 62.11% |
| 2012 | -6.19 Million USD | 19.45% |
| 2011 | -7.68 Million USD | -13.99% |
| 2010 | -6.74 Million USD | -4.13% |
| 2009 | 5.54 Million USD | -74.08% |
| 2008 | -3.72 Million USD | 65.19% |
| 2007 | -10.71 Million USD | 56.26% |
| 2006 | -14.33 Million USD | 29.12% |
| 2005 | -34.47 Million USD | -116.06% |
| 2004 | -15.95 Million USD | -356.77% |
| 2003 | -3.49 Million USD | -40605.7% |
| 2002 | -8582.00 USD | -50.03% |
| 2001 | -5720.00 USD | -70.54% |
| 2000 | -3354.00 USD | -112.01% |
| 1999 | -1582.00 USD | -149.53% |
| 1998 | -634.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.43 Million USD | 1.68% |
| 2024 Q1 | -6.12 Million USD | 9.14% |
| 2024 Q3 | -3.21 Million USD | 6.38% |
| 2023 Q1 | 1.75 Million USD | 119.73% |
| 2023 FY | - USD | 51.14% |
| 2023 Q3 | -2.23 Million USD | 60.22% |
| 2023 Q2 | -5.61 Million USD | -419.18% |
| 2023 Q4 | -4.36 Million USD | -95.42% |
| 2022 Q2 | -2.06 Million USD | 52.12% |
| 2022 Q3 | -4.27 Million USD | -107.05% |
| 2022 Q1 | -4.31 Million USD | -71.54% |
| 2022 FY | - USD | -120.59% |
| 2022 Q4 | -8.9 Million USD | -108.41% |
| 2021 FY | - USD | 23.25% |
| 2021 Q1 | -2.92 Million USD | 27.01% |
| 2021 Q2 | -2.95 Million USD | -0.92% |
| 2021 Q3 | -3.11 Million USD | -5.52% |
| 2021 Q4 | -2.51 Million USD | 19.42% |
| 2020 Q2 | -2.85 Million USD | -12.57% |
| 2020 Q1 | -2.53 Million USD | -41.42% |
| 2020 FY | - USD | -68.96% |
| 2020 Q4 | -4.01 Million USD | -25.45% |
| 2020 Q3 | -3.19 Million USD | -12.06% |
| 2019 FY | - USD | 32.89% |
| 2019 Q3 | -1.34 Million USD | 46.97% |
| 2019 Q4 | -1.79 Million USD | -33.41% |
| 2019 Q1 | -3.06 Million USD | 9.45% |
| 2019 Q2 | -2.53 Million USD | 17.19% |
| 2018 Q2 | -1.99 Million USD | 33.89% |
| 2018 Q3 | -2.74 Million USD | -37.54% |
| 2018 Q4 | -3.38 Million USD | -23.23% |
| 2018 Q1 | -3.01 Million USD | -23.53% |
| 2018 FY | - USD | 6.68% |
| 2017 Q4 | -2.44 Million USD | -0.06% |
| 2017 FY | - USD | -3.82% |
| 2017 Q3 | -2.44 Million USD | 25.09% |
| 2017 Q2 | -3.25 Million USD | 14.06% |
| 2017 Q1 | -3.79 Million USD | -67.67% |
| 2016 Q1 | -2.7 Million USD | -668.94% |
| 2016 FY | - USD | -239.24% |
| 2016 Q2 | -3.27 Million USD | -21.24% |
| 2016 Q3 | -3.25 Million USD | 0.69% |
| 2016 Q4 | -2.26 Million USD | 30.5% |
| 2015 Q3 | -1.55 Million USD | 11.67% |
| 2015 Q4 | -351.41 Thousand USD | 77.34% |
| 2015 FY | - USD | 68.98% |
| 2015 Q2 | -1.75 Million USD | -756.61% |
| 2015 Q1 | 267.4 Thousand USD | 107.68% |
| 2014 Q4 | -3.48 Million USD | -20.49% |
| 2014 FY | - USD | -365.41% |
| 2014 Q1 | -1.07 Million USD | -38.7% |
| 2014 Q2 | -3.47 Million USD | -224.05% |
| 2014 Q3 | -2.88 Million USD | 16.89% |
| 2013 FY | - USD | 62.11% |
| 2013 Q1 | 3.98 Million USD | 327.06% |
| 2013 Q2 | -2.06 Million USD | -151.9% |
| 2013 Q4 | -773.44 Thousand USD | 77.83% |
| 2013 Q3 | -3.48 Million USD | -68.81% |
| 2012 FY | - USD | 19.45% |
| 2012 Q4 | -1.75 Million USD | -32.45% |
| 2012 Q3 | -1.32 Million USD | -0.57% |
| 2012 Q2 | -1.31 Million USD | 23.2% |
| 2012 Q1 | -1.71 Million USD | 53.5% |
| 2011 Q3 | -1.12 Million USD | -1.47% |
| 2011 Q4 | -3.68 Million USD | -226.81% |
| 2011 FY | - USD | -13.99% |
| 2011 Q1 | -1.03 Million USD | 41.6% |
| 2011 Q2 | -1.11 Million USD | -7.69% |
| 2010 FY | - USD | -4.13% |
| 2010 Q1 | -1.49 Million USD | -36.07% |
| 2010 Q2 | -1.11 Million USD | 25.49% |
| 2010 Q4 | -1.76 Million USD | 25.68% |
| 2010 Q3 | -2.37 Million USD | -114.16% |
| 2009 Q2 | -1.66 Million USD | 38.75% |
| 2009 Q1 | -2.72 Million USD | -287.69% |
| 2009 Q4 | -1.09 Million USD | -10.52% |
| 2009 FY | - USD | -74.08% |
| 2009 Q3 | -990.84 Thousand USD | 40.61% |
| 2008 Q4 | -702.54 Thousand USD | 8.69% |
| 2008 Q3 | -769.44 Thousand USD | -218.26% |
| 2008 Q2 | 650.62 Thousand USD | 151.86% |
| 2008 Q1 | -1.25 Million USD | 82.17% |
| 2008 FY | - USD | 65.19% |
| 2007 FY | - USD | 56.26% |
| 2007 Q4 | -7.03 Million USD | -21.81% |
| 2007 Q3 | -5.77 Million USD | -205.75% |
| 2007 Q2 | 5.46 Million USD | 263.58% |
| 2007 Q1 | -3.33 Million USD | -223.32% |
| 2006 Q1 | -2.1 Million USD | 89.83% |
| 2006 Q4 | -1.03 Million USD | 70.77% |
| 2006 Q3 | -3.53 Million USD | 40.39% |
| 2006 Q2 | -5.92 Million USD | -181.2% |
| 2006 FY | - USD | 29.12% |
| 2005 Q3 | -2.74 Million USD | 55.33% |
| 2005 Q1 | -9.27 Million USD | -50.01% |
| 2005 Q2 | -6.15 Million USD | 33.68% |
| 2005 FY | - USD | -116.06% |
| 2005 Q4 | -20.72 Million USD | -653.77% |
| 2004 Q2 | -1.38 Million USD | 81.0% |
| 2004 Q1 | -7.27 Million USD | -65.67% |
| 2004 Q3 | -1.11 Million USD | 19.38% |
| 2004 Q4 | -6.18 Million USD | -455.17% |
| 2004 FY | - USD | -356.77% |
| 2003 Q1 | -147.19 Thousand USD | 0.0% |
| 2003 Q3 | -325.88 Thousand USD | 24.74% |
| 2003 Q4 | -4.39 Million USD | -1247.5% |
| 2003 FY | - USD | -40605.7% |
| 2003 Q2 | -432.98 Thousand USD | -194.16% |
| 2002 Q1 | -210.00 USD | 97.43% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 100.0% |
| 2002 FY | - USD | -50.03% |
| 2001 Q3 | -105.00 USD | 0.0% |
| 2001 Q1 | -5159.00 USD | -2766.11% |
| 2001 FY | - USD | -70.54% |
| 2001 Q4 | -8162.00 USD | -7673.33% |
| 2001 Q2 | -105.00 USD | 97.96% |
| 2000 Q4 | -180.00 USD | -13.21% |
| 2000 FY | - USD | -112.01% |
| 2000 Q2 | -222.00 USD | 92.69% |
| 2000 Q3 | -159.00 USD | 28.38% |
| 2000 Q1 | -3037.00 USD | 0.0% |
| 1999 Q2 | -159.00 USD | 0.0% |
| 1999 Q3 | -158.00 USD | 0.63% |
| 1999 Q4 | - USD | 100.0% |
| 1999 FY | - USD | -149.53% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 95.51% |
| Prenetics Global Limited | -47.89 Million USD | 79.975% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -468.526% |
| CareDx, Inc | -89.65 Million USD | 89.303% |
| Exact Sciences Corporation | 41.87 Million USD | 122.903% |
| Exagen Inc. | -19.15 Million USD | 49.924% |
| Inotiv, Inc. | -26.5 Million USD | 63.816% |
| Guardant Health, Inc. | -433.3 Million USD | 97.787% |
| Biodesix, Inc. | -37.1 Million USD | 74.15% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -285.932% |
| Precipio, Inc. | -4.31 Million USD | -122.118% |
| iSpecimen Inc. | -9.1 Million USD | -5.353% |
| Natera, Inc. | -383.27 Million USD | 97.498% |
| Aspira Women's Health Inc. | -16.49 Million USD | 41.841% |
| Standard BioTools Inc. | -54.45 Million USD | 82.388% |
| 23andMe Holding Co. | -291.87 Million USD | 96.714% |
| Castle Biosciences, Inc. | -45.02 Million USD | 78.698% |
| Personalis, Inc. | -96.8 Million USD | 90.093% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 91.842% |
| OpGen, Inc. | -29.51 Million USD | 67.5% |
| T2 Biosystems, Inc. | -43.87 Million USD | 78.14% |
| Myriad Genetics, Inc. | -67.8 Million USD | 85.854% |
| ICON Public Limited Company | 1.63 Billion USD | 100.588% |
| NeoGenomics, Inc. | -17.6 Million USD | 45.527% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -468.526% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 100.788% |
| RadNet, Inc. | 292.78 Million USD | 103.276% |
| MDxHealth SA | -30.46 Million USD | 68.521% |
| Psychemedics Corporation | -251 Thousand USD | -3721.132% |
| Illumina, Inc. | -608 Million USD | 98.423% |
| Check-Cap Ltd. | -17.64 Million USD | 45.657% |
| Twist Bioscience Corporation | -176.7 Million USD | 94.572% |
| DarioHealth Corp. | -53.49 Million USD | 82.071% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 79.397% |
| Sera Prognostics, Inc. | -35.28 Million USD | 72.82% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 1.98% |
| OPKO Health, Inc. | -65.51 Million USD | 85.361% |
| Medpace Holdings, Inc. | 363.15 Million USD | 102.641% |
| Neogen Corporation | 182.59 Million USD | 105.253% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -8.857% |
| Prenetics Global Limited | -47.89 Million USD | 79.975% |
| Mainz Biomed B.V. | -25.01 Million USD | 61.653% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -25.713% |
| Trinity Biotech plc | -24.09 Million USD | 60.2% |
| Neuronetics, Inc. | -22.75 Million USD | 57.858% |
| Sotera Health Company | 514.14 Million USD | 101.865% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -25.713% |